The aim of this study was to evaluate the risk of death due to coronary heart disease (CHD), stroke, or any disease among female users of estradiol-based hormone therapy (HT) regimens in a nationwide study in Finland. A total of 489,105 women who used hormone therapy from 1994 to 2009 were followed. Overall, the researchers found that the risk of CHD was significantly reduced by 18-54% in HT users and this reduction was positively related to HT exposure time. The risk of stroke was reduced by 18-39% in HT users, but this reduction was not related to HT exposure time. The risk of all-cause mortality was also reduced in HT users by 12-38%, and this reduction was found to have an almost linear relationship with HT exposure time.